Hepatitis B Management in Special Populations

  • Author: Alessandra Mangia, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 6/4/18 (What's New)

Summary

  • Treatment in the third trimester of pregnancy may lower risk of perinatal HBV transmission
  • Maternal viremia plays a significant role in perinatal transmission. Studies have reported increased risk of transmission with high levels of viremia (> 8 log10 copies/mL or ~ 7.3 log10 IU/mL)[Burk 1994; Xu 2009; van Zonneveld 2003]
  • AASLD guidance panel suggests antiviral therapy during third trimester to decrease risk of HBV perinatal transmission in HBsAg-positive pregnant women with HBV DNA > 200,000 IU/mL[AASLD HBV]

    Action required

    Keywords: Hepatitis B, Hepatitis B-Special Populations, Hepatitis B-Treatment, Pregnancy

    ©2018 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.